Articles tagged with Drug Studies
Researchers at Scripps Research Institute have received a nearly $4.5 million grant with the possibility of up to $10 million to complete preclinical studies on a new anti-migraine drug candidate. The compound has shown promising results in treating stress-induced migraine and may be developed into a once-a-day pill.
ESC Congress 2015 saw a record-breaking attendance of 32,773 registrations, featuring 28 clinical Hot Line presentations, 18 Clinical Trial Updates, and 20 Registry studies. Key findings included the use of spironolactone for resistant hypertension and its positive implications for clinical practice.
A study published in JAMA found that finerenone significantly reduces albuminuria in patients with diabetes and kidney disease. The medication also shows a lower risk of hyperkalemia compared to other treatments.
Researchers at Massachusetts General Hospital found that urate stimulates astrocytes to activate an antioxidant pathway believed to have a role in several neurodegenerative disorders. A phase 3 trial of a urate-elevating drug, led by Dr. Michael Schwarzschild, is planned to enroll 270 patients with early-stage Parkinson's disease.
Dr. Peter Berger suggests that the expensive drug offers no clear safety benefits over heparin, which is widely used and effective in lower doses. The MATRIX Trial found no advantages of bivalirudin over heparin in preventing bleeding complications during cardiac stent placement.
A randomized controlled trial found that a self-management support service improved patients' symptoms and recovery scores. The program combined behavioral therapy with recovery-oriented approach, focusing on achieving life goals despite symptoms. Participants showed significant improvements compared to usual care.
The ELIXA trial demonstrated that lixisenatide, a GLP-1 receptor agonist, did not increase or decrease the rate of cardiovascular events compared to placebo. The study found a modest benefit in weight gain, but also identified patients with heart failure as being at high risk of all-cause death.
A new analysis of the TECOS study adds heart failure data to confirm sitagliptin's cardiovascular safety. The findings provide reassurance to patients and prescribers about the drug's risk profile.
A new study found that antiarrhythmia drug therapy after radiofrequency catheter ablation for atrial fibrillation does not reduce arrhythmia recurrence rates at one year. The treatment, which had shown a temporary benefit in earlier studies, lost its effectiveness once the medication was stopped.
A new Phase III clinical trial indicates cariprazine may treat negative symptoms associated with schizophrenia, including lack of emotion and social withdrawal. Researchers found a statistically significant improvement in the PANSS-NFS scale relative to risperidone after 26 weeks of treatment.
The CIRCUS trial found that cyclosporine did not reduce all-cause death, hospitalization for heart failure, or adverse left ventricular remodelling in STEMI patients undergoing PCI. The study suggested that targeting reperfusion injury remains a major challenge for PCI cardiologists.
A recent trial published at ESC Congress 2015 found that patient education programs did not significantly impact apixaban adherence. Adherence rates were high across both the control and education groups, with minimal difference observed between the two.
A new study published in the American Journal of Psychiatry has discovered a predictive fMRI-derived measure that significantly predicts patients' response to antipsychotic medication. This breakthrough enables the use of brain scans as a tool for guiding treatment and improving patient outcomes.
Daratumumab, a monoclonal antibody targeting CD38, showed significant promise against difficult-to-treat disease in patients with advanced multiple myeloma, achieving durable responses in 36% of patients, including complete remissions and very good partial responses.
Studies found that cannabis use is associated with smaller left amygdala and right ventral striatum volumes, but no causal link was established. An editorial warns of potential risks for individuals with a genetic predisposition to schizophrenia, particularly women.
A NIHR-funded study has found that repositioning patients after the Valsalva manoeuvre significantly increases its success rate in treating supraventricular tachycardia. The modified technique improved heart rhythm return rates from 17.5% to 43.5%, offering a cost-free and comfortable option for patients.
A new analysis found that patients taking certain heart medications to manage stress may have a longer survival time than those not taking these drugs. Nonselective beta blockers showed the most significant benefit in extending median survival time, particularly among patients with hypertension.
A population-based case-control study found that long-term, continuous use of low-dose aspirin and nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with decreased colorectal cancer risk. The study also suggests that higher COX-2 selectivity in nonaspirin NSAIDs may offer greater protection.
A randomized clinical trial found that discontinuing antihypertensive therapy in patients 75 and older with mild cognitive deficits did not improve short-term cognitive or general daily functioning. The study suggests that continuing antihypertensive therapy may be the best option for these patients.
Researchers from MSK Cancer Center announce results from the first published basket study, a clinical trial design that explores drug responses based on specific tumor mutations. The study found preliminary clinical efficacy of vemurafenib in multiple non-melanoma BRAFV600-mutated cancers.
Researchers predict a 50-76% decrease in Medicaid payments for antipsychotic medicines by 2016 and 2019, respectively. Generic versions of these medications will become more widely available, leading to substantial financial savings.
A new delayed-release metformin treatment has been developed to target the lower bowel and limit absorption into the blood. The treatment may help 40% of type 2 diabetes patients who currently can't take metformin due to impaired kidney function.
A study of 900 cancer patients found that heparin treatment did not significantly reduce recurrent blood clots or deaths compared to warfarin, but was associated with lower nonmajor bleeding rates. Heparin was also shown to be safe in this population, supporting its use over warfarin.
A large-scale analysis of published research studies found that yoga therapy was most often used for mental health, cardiovascular disease, and respiratory disease. The study, published in The Journal of Alternative and Complementary Medicine, analyzed 28,000 study participants from 29 countries over 46 years.
The ECOG-ACRIN Cancer Research Group has opened the National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) phase II precision medicine trial. The trial seeks to enroll approximately 3,000 adults with solid tumors or lymphoma who have returned or worsened after standard therapy.
The Massachusetts Rett Syndrome Association and Rettsyndrome.org are partnering to support a Phase 2b clinical trial of IGF-1 for the treatment of Rett syndrome. The trial, funded by a $439,000 grant from Rettsyndrome.org, aims to develop new biomarkers and treatments for the condition.
A comprehensive review of 7000 patients found that listening to music significantly reduces pain medication use and reports more satisfaction after surgery. Patients who selected their own music experienced a slight but non-significant reduction in pain, highlighting the importance of patient choice.
A new study found that GeneSight CPGx precision medicine testing improves medication adherence and reduces polypharmacy in patients treated with antidepressants and antipsychotics. The test resulted in substantial cost savings of $1,036 per year per patient.
A study by Northwestern University researchers found an intrinsic biological difference in the molecular regulation of synapses in the hippocampus between males and females. The drug URB-597 increased inhibitory effect in females, causing a decrease in neurotransmitter release, but had no effect in males.
Most antidepressant efficacy studies (AETs) now exclude a significant proportion of depressed patients, including those with comorbid psychiatric disorders and low rating scale scores. This trend suggests that AETs may be even less generalizable than previously thought, limiting their applicability to real-world populations.
A study analyzed clinical evidence of high-risk therapeutic devices approved through the FDA PMA pathway between 2010 and 2011, finding significant variation in the number and quality of premarket and postmarket studies. Only a few studies were completed, often focusing on surrogate markers and short periods of follow-up.
The Barbara Ann Karmanos Cancer Institute, in partnership with Wayne State University School of Medicine, is one of the lead centers participating in the National Cancer Institute's MATCH Trial. The trial seeks to determine whether targeted therapies for people with tumors having specific gene mutations will be effective.
A new technique helps doctors optimize cancer treatment doses in phase I/II clinical trials. The Optimal Two-Cycle Dose-Finding Design uses a patient's cycle 1 data to set a dose level for the second cycle, improving patient benefit and controlling toxicity risk.
A new study from Northwestern Medicine finds that seniors are more likely to be readmitted to the hospital within 30 days of ambulatory surgery, with age being an independent risk factor. The likely cause is difficulty understanding medication dosing and discharge instructions, as well as cognitive impairment among older patients.
A LA BioMed researcher is launching a study of medication adherence among dialysis patients, aiming to improve patient health outcomes. The researcher will examine the factors contributing to non-adherence and its impact on cardiovascular disease risk.
A phase 1 trial demonstrates the safety and effectiveness of resiquimod gel in treating early-stage cutaneous T cell lymphoma, causing regression of both treated and untreated tumor lesions. The treatment also enhances immune response, leading to healing of even untreated lesions.
A preclinical randomized controlled trial was conducted to evaluate a potential stroke therapy that had shown promise in one mouse model but not another. The study found that the treatment's success may depend on the type and severity of the stroke, suggesting improved clinical trial design could have mitigated this issue.
Patients with metastatic prostate cancer who received a two-drug combination of chemotherapy and hormone blocker lived longer than those on hormone-blocker alone, surviving for 57.6 months versus 44 months. The treatment also delayed disease progression by six months.
Large-budget clinical trials evaluating drugs or dietary supplements for cardiovascular disease reported fewer positive outcomes after new transparent reporting standards were implemented around 2000. The study found that 57% of trials from 1970-1999 reported positive results, compared to only 8% of trials from 2000-2012.
Researchers from the University of Arizona College of Medicine - Phoenix conducted a study on osteopathic manipulative therapy (OMT) in an in vitro setting. The results showed that OMT had profound effects on cellular processes, including proliferation, apoptosis, and cytokine production.
Researchers found that gout medications targeting uric acid and adenosine triphosphate can protect against alcohol-induced liver damage and inflammation. These findings suggest clinical trials for humans with alcoholic liver disease should be considered to prevent or treat acute episodes of alcoholic hepatitis.
Researchers found that mindfulness meditation can decrease unconscious influences motivating smokers to smoke, reducing craving rates by 60% in a 2-week study. Integrative body-mind training also decreases stress hormone cortisol levels and increases immune reactivity.
Researchers found that patients with pharmacist-included care teams had better blood pressure control results than those without, with a systolic blood pressure drop of 6.1 mmHg after nine months.
A big data study found that triamterene significantly lowers blood pressure when taken with hydrochlorothiazide, a commonly prescribed diuretic. The combination of the two drugs consistently reduces blood pressure in patients with or without other antihypertensive agents.
A study found that tailored mobile health technologies can help patients with chronic kidney disease take their medications appropriately, with a 5% error rate. The technologies were designed to provide safe and easy-to-use medication guidance for patients.
Researchers analyzed data from the Irish Longitudinal Study on Ageing and found a significant link between serious falls causing injury in older men taking certain medicines with potent anti-cholinergic effects. The risk was more than twice as likely in men compared to women.
Outpatient pharmacy expenditures totaled $475,718,130 for publicly insured children with serious chronic illness in California. Antihemophilic factor was the most expensive medication, accounting for 98% of its class's expenditures and 41% of total pharmacy expenditures.
A study found that white patients and larger, well-supported institutions have higher participation rates in pharmacogenomic trials. Conversely, racial diversity at hospitals decreases participation rates for both white and nonwhite patients.
A study found significant improvements in insurance coverage, access to a personal physician and medications, affordability, and health after the ACA's first two open enrollment periods. The largest gains were among racial/ethnic minorities, suggesting reduced disparities in access to care.
A recent study found that US NICU admission rates have increased for newborns of all birth weights, including normal-weight and term infants. The researchers looked at data from nearly 18 million live births between 2007 and 2012 and found a significant increase in NICU admissions.
A Phase 1 trial of LOXO-101 demonstrated a rapid and significant response in the first patient with a TRK fusion cancer. The patient's tumors substantially regressed after four months of treatment, meeting partial response criteria.
Researchers found that low-dose lithium reduced involuntary motor movements in Parkinson's disease mice, boosting dopamine synthesis via inhibition of calpain-1. This study adds to evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable condition.
A recent year-long study reveals that 40% of patients with chronic obstructive pulmonary disease (COPD) experience falls, with over 75% falling multiple times. The study identifies several factors linked to an increased risk of falling, including smoking, other illnesses, and taking multiple medications.
Two classes of inexpensive generic drugs, aromatase inhibitors and bisphosphonates, have been shown to improve survival prospects for postmenopausal women with early breast cancer. The combination of the two types of drug may also increase benefits while decreasing some side-effects.
A study published in The New England Journal of Medicine reports that an experimental compound, AVI-7288, protected nonhuman primates against the deadly Marburg virus. The compound showed efficacy even when administered after exposure to the virus. Phase I clinical trial results also indicated safety and tolerability.
A major re-analysis of a flagship study on deworming children has questioned the finding that it increases school attendance. The original trial reported improved attendance among untreated schools near treatment sites, but the new analysis found no evidence to support this claim.
A US study found that most participants in an NIH-funded study took anti-HIV medication for PrEP, a strategy for HIV prevention. The study enrolled 557 men who have sex with men and transgender women at high risk for HIV infection, and showed moderate adherence to Truvada-based oral PrEP.
A new study suggests that ultra-brief pulse stimulation is almost as effective as standard ECT in treating severe depression, but with significantly fewer cognitive side effects. The treatment has the potential to benefit up to 10,000 Australians who have not responded to first-line treatments.
Researchers at University of California, San Diego School of Medicine have developed a novel treatment regimen that effectively treats hepatitis C virus (HCV) in patients co-infected with human immunodeficiency virus type 1 (HIV), with a 97% success rate
Researchers found no statistically significant association between pioglitazone use and bladder cancer risk. However, a small increased risk was observed, as well as associations with increased prostate and pancreatic cancer risks.